Histoplasmosis Treatment Stopped Early in Study
Immunocompromised adults saw low relapse rates after ending antifungal therapy before 12 months.
Updated on Sept. 23, 2026 in Diseases — General
A study published September 12, 2026, examined histoplasmosis outcomes in immunocompromised patients, finding that relapse occurred in 6.6% of those who stopped antifungal therapy early. The research tracked 106 patients treated between 2005 and 2025 to evaluate if shorter treatment durations were safe.
Why it matters
Understanding if shorter antifungal courses are effective helps clinicians balance the need for infection control against the burden of long-term therapy. This research provides new data for immunocompromised patients navigating treatment timelines for serious fungal infections.
In a retrospective cohort study of 106 immunocompromised adults, researchers analyzed infection outcomes following early discontinuation of antifungal therapy. While relapse remained low at 6.6%, the shorter treatment group experienced an 80% rehospitalization rate compared to 52.1% in the guideline group.
The players
Indiana University School of Medicine
A medical research and education institution based in Indianapolis that conducted the study.
The details
The study assessed the impact of antifungal therapy duration by comparing clinical outcomes in patients who completed the standard 12-month course against those who stopped treatment early. Researchers at the Indiana University School of Medicine evaluated these outcomes through longitudinal follow-up, observing an adjusted hazard ratio of 2.34 for treatment duration. The team also examined patient markers, noting that individuals with baseline antigen levels between 10.1 and 20 ng/mL faced lower odds of adverse events.
Timeline
2005 to 2025 served as the study period for patient antifungal therapy.
September 12, 2026, marked the publication of the findings in Open Forum Infectious Diseases.
Health Landscape
This retrospective study adds to the existing clinical literature by examining the safety of abbreviated antifungal treatment protocols for immunocompromised patients. It marks a shift toward evaluating whether individualized treatment durations can maintain efficacy while potentially reducing the long-term medication burden.
If you are managing histoplasmosis, this study highlights the importance of discussing treatment duration and rehospitalization risks with your infectious disease specialist. Be sure to ask your doctor about your specific baseline antigen levels and how they might influence your care plan.
The takeaway
While early discontinuation of therapy showed low relapse rates in this study, the high rehospitalization rates underscore the necessity of close clinical monitoring. Always consult your physician before making any changes to your prescribed antifungal therapy duration.
Further reading
For additional context on managing complex fungal conditions, explore our Diseases — General archives.
Source note: This article includes information reported by Medscape.
